<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The outcomes of 39 patients with <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> who had undergone allogeneic bone marrow transplantation (BMT) from September 1986 to March 1992 were reported </plain></SENT>
<SENT sid="1" pm="."><plain>The length of follow-up was six to 50 months </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, eight patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, seven patients with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, two patients with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and two patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> were included </plain></SENT>
<SENT sid="3" pm="."><plain>Major complications were <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) (17 cases out of 36 evaluable cases; 47 percent), <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD (13/25; 52 percent), <z:hpo ids='HP_0100806'>sepsis</z:hpo> (20/41; 49 percent), <z:hpo ids='HP_0006515'>interstitial pneumonitis</z:hpo> (IP) (10/30; 33 percent), and <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">veno-occlusive disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>) of the liver (5/41; 12 percent) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD were well managed with cyclosporin, <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, and steroids </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> of the liver seemed to be associated with the pretransplant regimen including <z:chebi fb="0" ids="28901">busulfan</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>The overall probability of disease free survival of 39 patients who had undergone allogeneic BMT was 0.56 </plain></SENT>
<SENT sid="7" pm="."><plain>This includes nine high risk cases such as HLA antigen mismatch between the donor and the recipient, and as in the second or subsequent remission or in relapsed cases </plain></SENT>
<SENT sid="8" pm="."><plain>The probability of disease free survival in patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> including high risk cases was 0.55 (n = 20), 0.71 (n = 7), and 0.50 (n = 8) respectively </plain></SENT>
<SENT sid="9" pm="."><plain>These results indicate that allogeneic BMT is the major therapeutic strategy for patients whose survival could not be expected by conventional chemotherapy and that drug intensification for conditioning regimen is also important </plain></SENT>
</text></document>